Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BMS-791325 in Subjects Chronically Infected With Hepatitis C Virus Genotype 1
Brief Summary: The primary purpose of this study is to evaluate the safety profile and tolerability of single oral doses of BMS-791325 in subjects with chronic hepatitis C infection


Options:
A: Arm Label: Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated-interferon-alfa-2a, Drug: Ribavirin | Arm Label: Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin; Type: EXPERIMENTAL; Interventions: Drug: Telaprevir, Drug: Pegylated-interferon-alfa-2a, Drug: Ribavirin | Arm Label: Placebo+Pegylated-interferon-alfa-2a+Ribavirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated-interferon-alfa-2a, Drug: Placebo, Drug: Ribavirin | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Pegylated-interferon-alfa-2a; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Placebo+Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir and then Pegylated-interferon-alfa-2a+Ribavirin, Telaprevir+Pegylated-interferon-alfa-2a+Ribavirin
B: Arm Label: 001 T(q8h) / PR; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Pegylated interferon alfa-2a, Drug: Telaprevir | Arm Label: 002 T(b.i.d.) / PR; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: Telaprevir, Drug: Pegylated interferon alfa-2a | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 001 T(q8h) / PR, 002 T(b.i.d.) / PR | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): 002 T(b.i.d.) / PR | Intervention Type: DRUG; Name: Pegylated interferon alfa-2a; Assigned to Arm(s): 001 T(q8h) / PR, 002 T(b.i.d.) / PR | Intervention Type: DRUG; Name: Telaprevir; Assigned to Arm(s): 001 T(q8h) / PR
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BMS-791325, Drug: Placebo | Intervention Type: DRUG; Name: BMS-791325; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1, 2, 3, 4
D: Arm Label: SOF/VEL; Type: EXPERIMENTAL; Interventions: Drug: SOF/VEL | Arm Label: SOF+RBV; Type: EXPERIMENTAL; Interventions: Drug: SOF, Drug: RBV | Intervention Type: DRUG; Name: SOF/VEL; Assigned to Arm(s): SOF/VEL | Intervention Type: DRUG; Name: SOF; Assigned to Arm(s): SOF+RBV | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): SOF+RBV

Answer: C